Related Experiment Video
Updated: Sep 10, 2025
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
Discovery of Selective PDE1 Inhibitors Alleviating Pulmonary Fibrosis by the Regulation of TGF-β/Smads and MAPK
Mei-Yan Jiang1, Qian Zhou2, Xiao-Long Tian1
1State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, P. R. China.
Abstract:
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease with limited treatment options. Our preliminary research identified phosphodiesterase 1 (PDE1) as a potential therapeutic target for IPF treatment. However, both the molecular recognition mechanism between PDE1 inhibitors and the protein, as well as the antifibrotic mechanism, remain incompletely understood. In this study, structural modifications were carried out on a pan-PDE inhibitor 1 we previously developed. The lead compound 4b exhibited an IC50 of 5 nM against PDE1, excellent selectivity across PDE subfamilies and favorable safety properties. Structure-activity relationship analysis combined with binding mode predictions demonstrated that targeting differential residues in the H-loop regions of PDEs is critical for improving selectivity over other PDEs. Furthermore, we demonstrated that the PDE1 inhibitor attenuated pulmonary fibrosis by suppressing both the TGF-β/Smad and MAPK pathways.
Insights
Researchers developed a novel phosphodiesterase 1 (PDE1) inhibitor, compound 4b, to treat idiopathic pulmonary fibrosis (IPF). This inhibitor shows high selectivity and effectively reduces lung fibrosis by targeting key molecular pathways.
Area of Science:
- Pharmacology and Drug Discovery
- Molecular Biology
- Pulmonary Medicine
Background:
- Idiopathic pulmonary fibrosis (IPF) is a severe, progressive, and fatal lung disease with limited therapeutic strategies.
- Phosphodiesterase 1 (PDE1) has been identified as a potential therapeutic target for IPF, but its inhibition mechanisms are not fully understood.
- Previous work identified a pan-PDE inhibitor (compound 1) as a starting point for developing more selective agents.
Purpose of the Study:
- To structurally modify a known pan-PDE inhibitor to develop a selective PDE1 inhibitor for IPF treatment.
- To elucidate the molecular recognition mechanism and structure-activity relationships (SAR) for improved PDE1 selectivity.
- To investigate the antifibrotic mechanisms of the developed PDE1 inhibitor in the context of IPF.
Main Methods:
- Synthesis and structural modification of a previously developed pan-PDE inhibitor.
- Biochemical assays to determine inhibitory activity (IC50) and selectivity against various PDE subfamilies.
- Structure-activity relationship (SAR) analysis and molecular docking to predict binding modes.
- In vitro studies to assess the compound's effect on TGF-β/Smad and MAPK signaling pathways.
Main Results:
- The lead compound, 4b, demonstrated potent inhibition of PDE1 with an IC50 of 5 nM.
- Compound 4b exhibited excellent selectivity across different phosphodiesterase (PDE) subfamilies and favorable safety profiles.
- SAR analysis and binding mode predictions highlighted the importance of targeting differential residues in PDE H-loop regions for selectivity.
- The PDE1 inhibitor effectively attenuated pulmonary fibrosis by suppressing both the TGF-β/Smad and MAPK signaling pathways.
Conclusions:
- Targeting PDE1 with selective inhibitors, like compound 4b, represents a promising therapeutic strategy for idiopathic pulmonary fibrosis.
- Optimizing interactions within the H-loop regions of PDEs is crucial for achieving high selectivity.
- The antifibrotic effects are mediated through the inhibition of critical fibrotic signaling cascades, including TGF-β/Smad and MAPK pathways.
Related Concept Videos
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:16TGF - β Signaling Pathway
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...